chr12-2053576-A-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 3P and 2B. PM2PP2BP4_Moderate
The NM_000719.7(CACNA1C):c.14A>G(p.Asn5Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 11/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: not found (cov: 31)
Consequence
CACNA1C
NM_000719.7 missense
NM_000719.7 missense
Scores
2
3
12
Clinical Significance
Conservation
PhyloP100: 2.18
Genes affected
CACNA1C (HGNC:1390): (calcium voltage-gated channel subunit alpha1 C) This gene encodes an alpha-1 subunit of a voltage-dependent calcium channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane segments and forms the pore through which ions pass into the cell. The calcium channel consists of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. There are multiple isoforms of each of these proteins, either encoded by different genes or the result of alternative splicing of transcripts. The protein encoded by this gene binds to and is inhibited by dihydropyridine. Alternative splicing results in many transcript variants encoding different proteins. Some of the predicted proteins may not produce functional ion channel subunits. [provided by RefSeq, Oct 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), CACNA1C. . Gene score misZ 6.4654 (greater than the threshold 3.09). Trascript score misZ 7.2674 (greater than threshold 3.09). GenCC has associacion of gene with intellectual disability, neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, Brugada syndrome, long QT syndrome, short QT syndrome, long qt syndrome 8, Timothy syndrome, Brugada syndrome 3.
BP4
Computational evidence support a benign effect (MetaRNN=0.21796432).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1C | NM_000719.7 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | ENST00000399655.6 | NP_000710.5 | |
CACNA1C | NM_001167623.2 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | ENST00000399603.6 | NP_001161095.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1C | ENST00000399603.6 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 5 | NM_001167623.2 | ENSP00000382512.1 | ||
CACNA1C | ENST00000399655.6 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | NM_000719.7 | ENSP00000382563.1 | ||
CACNA1C | ENST00000406454.8 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 5 | ENSP00000385896.3 | |||
CACNA1C | ENST00000399634.6 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 5 | ENSP00000382542.2 | |||
CACNA1C | ENST00000347598.9 | c.14A>G | p.Asn5Ser | missense_variant | 1/49 | 1 | ENSP00000266376.6 | |||
CACNA1C | ENST00000344100.7 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000341092.3 | |||
CACNA1C | ENST00000327702.12 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 1 | ENSP00000329877.7 | |||
CACNA1C | ENST00000399617.6 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 5 | ENSP00000382526.1 | |||
CACNA1C | ENST00000399638.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 1 | ENSP00000382547.1 | |||
CACNA1C | ENST00000335762.10 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 5 | ENSP00000336982.5 | |||
CACNA1C | ENST00000399606.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/48 | 1 | ENSP00000382515.1 | |||
CACNA1C | ENST00000399621.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382530.1 | |||
CACNA1C | ENST00000399637.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382546.1 | |||
CACNA1C | ENST00000402845.7 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000385724.3 | |||
CACNA1C | ENST00000399629.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382537.1 | |||
CACNA1C | ENST00000682336.1 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | ENSP00000507898.1 | ||||
CACNA1C | ENST00000399591.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/46 | 1 | ENSP00000382500.1 | |||
CACNA1C | ENST00000399595.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/46 | 1 | ENSP00000382504.1 | |||
CACNA1C | ENST00000399649.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/46 | 1 | ENSP00000382557.1 | |||
CACNA1C | ENST00000399597.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382506.1 | |||
CACNA1C | ENST00000399601.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382510.1 | |||
CACNA1C | ENST00000399641.6 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382549.1 | |||
CACNA1C | ENST00000399644.5 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | 1 | ENSP00000382552.1 | |||
CACNA1C | ENST00000682835.1 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | ENSP00000507282.1 | ||||
CACNA1C | ENST00000683482.1 | c.14A>G | p.Asn5Ser | missense_variant | 1/47 | ENSP00000507169.1 | ||||
CACNA1C | ENST00000682686.1 | c.14A>G | p.Asn5Ser | missense_variant | 1/46 | ENSP00000507309.1 | ||||
CACNA1C | ENST00000682544.1 | c.140-61648A>G | intron_variant | ENSP00000507184.1 | ||||||
CACNA1C | ENST00000683824.1 | c.140-61648A>G | intron_variant | ENSP00000507867.1 | ||||||
CACNA1C | ENST00000682462.1 | c.140-61648A>G | intron_variant | ENSP00000507105.1 | ||||||
CACNA1C | ENST00000683781.1 | c.140-61648A>G | intron_variant | ENSP00000507434.1 | ||||||
CACNA1C | ENST00000683840.1 | c.140-61648A>G | intron_variant | ENSP00000507612.1 | ||||||
CACNA1C | ENST00000683956.1 | c.140-61648A>G | intron_variant | ENSP00000506882.1 | ||||||
CACNA1C | ENST00000480911.6 | n.14A>G | non_coding_transcript_exon_variant | 1/27 | 5 | ENSP00000437936.2 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 05, 2016 | Variant summary: The CACNA1C c.14A>G (p.Asn5Ser) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a benign outcome for this variant (SNPs&GO not captured due to low reliability index). This variant is absent in 52688 control chromosomes. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories; nor evaluated for functional impact by in vivo/vitro studies. Because of the absence of clinical information and the lack of functional studies, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available. - |
Long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 13, 2022 | This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CACNA1C protein function. ClinVar contains an entry for this variant (Variation ID: 496070). This variant has not been reported in the literature in individuals affected with CACNA1C-related conditions. This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 5 of the CACNA1C protein (p.Asn5Ser). - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 27, 2022 | The p.N5S variant (also known as c.14A>G), located in coding exon 1 of the CACNA1C gene, results from an A to G substitution at nucleotide position 14. The asparagine at codon 5 is replaced by serine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;T;.;.;.;.;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
.;N;.;N;N;N;N;N;N;N;N;N;N;N;N;N;.;N;N;N;.;.;.
MutationTaster
Benign
N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N
REVEL
Uncertain
Sift
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
Sift4G
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
Polyphen
0.93, 0.056, 0.091, 0.015, 0.0050
.;P;.;B;P;B;P;B;P;P;P;B;B;P;P;B;.;P;P;.;.;.;.
Vest4
MutPred
Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);Gain of catalytic residue at T6 (P = 0.0155);
MVP
MPC
2.0
ClinPred
D
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at